{
    "clinical_study": {
        "@rank": "50271", 
        "arm_group": {
            "arm_group_label": "SGN-CD33A", 
            "arm_group_type": "Experimental", 
            "description": "SGN-CD33A"
        }, 
        "brief_summary": {
            "textblock": "This study will examine the safety profile of SGN-CD33A administered as a single agent. The\n      main purpose of the study is to find the maximum tolerated dose (MTD, which is the highest\n      dose that does not cause unacceptable side effects) of SGN-CD33A in patients with acute\n      myeloid leukemia (AML).  The MTD will be determined by observing the dose-limiting\n      toxicities (the side effects that prevent further increases in dose) of SGN-CD33A.  In\n      addition, the pharmacokinetic profile and anti-leukemia activity of SGN-CD33A will be\n      assessed."
        }, 
        "brief_title": "A Safety Study of SGN-CD33A in AML Patients", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myelogenous Leukemia", 
            "Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute myeloid leukemia, positive for CD33\n\n          -  Eastern Cooperative Onocology Group status of 0 or 1\n\n          -  Adequate baseline renal and hepatic function\n\n          -  Central venous access\n\n          -  Either achieved complete remission (greater than 12 weeks in duration) with initial\n             induction/consolidation and have experienced relapse of disease or declined treatment\n             with high-dose induction/consolidation\n\n          -  Bone marrow blasts greater than or equal to 5% for relapsed patients, or greater than\n             or equal to 20% for untreated patients\n\n        Exclusion Criteria:\n\n          -  Inadequate lung function\n\n          -  Prior stem cell transplant\n\n          -  High-dose chemotherapy within 4 weeks of study drug\n\n          -  Antileukemia treatment within 14 days of study drug (other than hydroxyurea or\n             6-mercaptopurine)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902329", 
            "org_study_id": "SGN33A-001"
        }, 
        "intervention": {
            "arm_group_label": "SGN-CD33A", 
            "description": "Given intravenously every 3 weeks", 
            "intervention_name": "SGN-CD33A", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Acute Myeloid Leukemia", 
            "Antibody-Drug Conjugate", 
            "CD33 Antigen", 
            "Immunotherapy", 
            "Drug Therapy", 
            "Acute Myelogenous Leukemia"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mkhurst@uab.edu", 
                    "last_name": "Kinley Hurst", 
                    "phone": "205-975-9481"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-3300"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }, 
                "investigator": {
                    "last_name": "Harry Erba, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hilam@coh.org", 
                    "last_name": "Pennie Hien Lam", 
                    "phone": "626-256-4673"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010-3000"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Anthony Stein", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Debra.Mimo@moffitt.org", 
                    "last_name": "Debra Mimo", 
                    "phone": "813-745-7362"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Lancet, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "CMLOISELLE@PARTNERS.ORG", 
                    "last_name": "Colleen Loiselle", 
                    "phone": "617-726-2261"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Amir Fathi, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "steine@mskcc.org", 
                    "last_name": "Eytan Stein", 
                    "phone": "212-639-3314"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Eytan Stein", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "finchec@ccf.org", 
                    "last_name": "Cassandra Fincher", 
                    "phone": "216-445-3795"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic, The"
                }, 
                "investigator": {
                    "last_name": "Anjali Advani, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Daryn.Flentje@hci.utah.edu", 
                    "last_name": "Daryn Flentje", 
                    "phone": "801-213-4230"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "University of Utah"
                }, 
                "investigator": {
                    "last_name": "Tibor Kovacsovics, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "korlowsk@fhcrc.org", 
                    "last_name": "Kaysey Orlowski", 
                    "phone": "206-667-1997"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center"
                }, 
                "investigator": {
                    "last_name": "Roland Walter, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia", 
        "overall_contact": {
            "email": "clinicaltrials@seagen.com", 
            "last_name": "Terri Lowe", 
            "phone": "866-333-7436"
        }, 
        "overall_official": {
            "affiliation": "Seattle Genetics, Inc.", 
            "last_name": "Samuel Blackman, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Through 1 month following last dose"
            }, 
            {
                "measure": "Incidence of laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Through 1 month following last dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902329"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Blood concentrations of SGN-CD33A and metabolites", 
                "safety_issue": "No", 
                "time_frame": "Through 3 weeks after dosing"
            }, 
            {
                "measure": "Incidence of antitherapeutic antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Through 1 month following last dose"
            }, 
            {
                "measure": "Rate of complete remission", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "measure": "Duration of complete remission", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 3 years"
            }, 
            {
                "measure": "Relapse-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 3 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 3 years"
            }
        ], 
        "source": "Seattle Genetics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seattle Genetics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}